Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

The osteoclast, bone remodelling and treatment of metabolic bone disease

Boyce, Brendan F., Rosenberg, Elizabeth, de Papp, Anne E., Duong, Le T. · 2012 · European Journal of Clinical Investigation

Abstract

Eur J Clin Invest 2012; 42 (12): 1332–1341 Background Bone remodelling maintains skeletal integrity by osteoclasts removing foci of damaged bone and osteoblasts replacing them with new bone. Diseases associated with increased bone resorption have increased remodelling often with inadequate bone formation and increased risk of fracture. New therapies are needed for these diseases to reduce resorption and increase formation. Design The molecular mechanisms regulating osteoclast and osteoblast functions have become better understood in the past 20 years and have led to questioning of the long‐held notion that osteoblastic cells have the dominant regulatory role over osteoclastic cells in bone remodelling. Here, we review current knowledge of how osteoclast formation and functions are regulated and describe how enhanced understanding of these has led to development of new drugs for the management of common bone diseases characterized by increased bone resorption. Results Osteoclast formation and functions are regulated by cytokines, especially receptor activator of NF‐κB ligand (RANKL) and macrophage‐colony‐stimulating factor (M‐CSF). The differentiation, activity and lifecycle of osteoclasts are regulated in part by other cells that reside within the bone. These include osteoblasts, osteocytes and immune cells, which express these cytokines in response to most factors that promote bone resorption. RANKL and M‐CSF activate numerous signalling pathways, which are potential targets for therapeutic intervention. Importantly, osteoclastic cells also function as positive and negative regulators of osteoblastic bone formation. Conclusions There are multiple targets within osteoclasts for pharmacologic intervention to prevent bone loss in osteoporosis and other resorptive bone diseases. However, novel therapies could also affect osteoblastic cell functions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2362.2012.02717.x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 184

Metadata

Authors
Boyce, B. F., Rosenberg, E., de Papp, A. E., & Duong, L. T.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2012-09-23
Volume
42
Issue
12
Pages
1332-1341
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W1557542853
Cited by
184
References
11
FWCI
6.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The osteoclast, bone remodelling and treatment of metabolic bone disease. https://app.cochat.ai/papers/10.1111/j.1365-2362.2012.02717.x
The paper
Boyce, B. F., Rosenberg, E., de Papp, A. E., & Duong, L. T. (2012). The osteoclast, bone remodelling and treatment of metabolic bone disease. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2012.02717.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.